<DOC>
	<DOCNO>NCT01256268</DOCNO>
	<brief_summary>The purpose study : - Test safety new investigational drug call MK-8669 ( ridaforolimus ) - Determine maximum tolerate dose MK-8669 - Determine effectiveness maximum tolerate dose MK-8669</brief_summary>
	<brief_title>Carboplatin/Taxol/Ridaforolimus Endometrial , Ovarian Solids</brief_title>
	<detailed_description>This phase 1A/1B study . Phase 1A design determine maximal tolerate dose ( MTD ) toxicity ridaforolimus combination paclitaxel carboplatin patient advance recurrent solid tumor . The MTD determine study recommend dose study phase 1B future phase 2 trial .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Must measurable disease evaluable disease . Measurable disease define least one lesion accurately measure least one dimension ( long dimension record ) . Each lesion must minimum size 10 mm CT scan ( CT scan slice thickness great 5 mm ) , 10 mm caliper measurement clinical exam 20 mm chest Xray . Lymph node must ≥ 15 mm short axis assess CT scan . Evaluable disease disease evident image meet Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 1.1 , however , meet tumor marker evaluation , e.g. , Gynecologic Cancer Intergroup ( GCIG ) criterion . Notes : ) If patient 's disease confine solitary lesion , neoplastic nature must confirm histology cytology unless accompany GCIG criterion clearly show new disease compare prior image . ii ) Disease previously irradiate field acceptable site measurable disease clear progression since completion radiotherapy . Age &gt; 18 year competent give inform consent . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 life expectancy least 60 day . Patients must adequate : Bone marrow function : Absolute neutrophil count ( ANC ) great equal 1,500/ul , equivalent Common Toxicity Criteria ( CTCAE v4.0 ) grade 1 . Platelets great equal 100,000/ul . ; Renal function : creatinine le equal 1.5 x institutional upper limit normal ( ULN ) , CTCAE v4.0 grade 1. ; Hepatic function : Bilirubin le equal 1.5 x ULN ( CTCAE v4.0 grade 1 ) . serum glutamic oxaloacetic transaminase ( SGOT ) alkaline phosphatase less equal 2.5 x ULN ( CTCAE v4.0 grade 1 ) . ; Neurologic function : Neuropathy ( sensory motor ) less equal CTCAE v4.0 grade 1. ; No chemotherapy , radiotherapy , biologic , hormonal , investigational drug therapy within 28 day prior start treatment study . Women childbearing potential ( WOCBP ) must negative serum pregnancy test prior study entry practice effective method birth control course study , manner risk failure minimize . Prior study enrollment , WOCBP must advise importance avoid pregnancy trial participation potential risk factor intentional pregnancy . Phase 1A Additional criterion applicable phase 1A Must pathologically confirm solid cancer locally advance metastatic cancer . Patient 's physician believe cancer advance , recurrent metastatic curable local measure ( i.e. , surgery , radiation , drug ) . Patient 's physician believe patient may potentially benefit combination therapy . Patients may three ( 3 ) prior cytotoxic chemotherapeutic regimen include prior treatment carboplatin paclitaxel . Chemotherapy drug change modification make reason progression consider separate regimen . Examples would drug change toxicity consolidation chemotherapy adjuvant treatment . Patients may receive number prior noncytotoxic regimen monoclonal antibody , cytokine , signal transduction inhibitor , hormonal therapy . Previous radiation therapy allow . Phase 1B Endometrial : Additional Inclusion Criteria Epithelial endometrial cancer . ( i.e . carcinosarcoma , leiomyosarcoma , endometrial stromal sarcoma exclude ) . May one prior chemotherapy endometrial cancer . Prior taxane platinum therapy allow long receive either adjuvant therapy response prior therapy least 6 month elapse since platinum treatment . Radiation sensitize chemotherapy count prior regimen . Must measurable disease Phase 1B Ovarian : Additional Inclusion Criteria Recurrent epithelial ovarian cancer ( stromal germ cell ovarian cancer ) Platinumsensitive define recurrence least 6 month ( 180 day ) last day primary adjuvant chemotherapy . Patients may retreat salvage line chemotherapy must platinumfree interval 6 month . Two ( 2 ) less prior therapy include adjuvant chemotherapy Measurable evaluable disease An upper gastrointestinal condition would impair swallow absorption oral medication Any serious illness medical condition would permit patient manage accord protocol , include , limited , follow : History significant neurologic psychiatric disorder ( e.g. , uncontrolled psychiatric disorder ) would impair ability obtain consent limit compliance study requirement Active uncontrolled serious infection Active peptic ulcer disease Patients follow cardiac condition : Uncontrolled angina myocardial infarction past six month ; Diagnosed suspect congenital long QT syndrome ; Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ; Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Fridericia Bazett 's correction Uncontrolled hypertension define systolic great 180 diastolic great 100 . History invasive malignancy last 3 year , exception nonmelanoma skin cancer , unless evidence recurrence cancer last two year . Serum creatinine &gt; 1.5 time institutional upper limit normal Patients take certain concomitant medication ( see ) . Patients enroll protocol stop medication washout period ≥14 day , unless otherwise note , do prior start ridaforolimus . There must least 14 day since prior ( current expectation receive ) CYP3A4 inhibitor include , limited , follow : Azole antifungal ( i.e. , ketoconazole , itraconazole , miconazole , fluconazole ) ; HIV protease inhibitor ( i.e. , indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) ; Clarithromycin ; Verapamil ; Erythromycin ; Delavirdine ; Diltiazem ; Nefazodone ; Telithromycin There must least 14 day since prior ( current expectation receive ) CYP3A4 inducer include , limited , follow Rifampin Phenytoin Rifabutin St.John 's wort Carbamazepine Efavirenz Phenobarbital Tipranavir Full dose anticoagulation warfarin ( coumadin ) vitamin K dependent anticoagulant . Lowdose prophylactic warfarin ( i.e . 1mg per day port prophylaxis ) allowable . Low molecular heparin ( e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ) allowable patient establish therapy . Have receive estimate dose radiation therapy &gt; 35 % bone marrow . Patients previously expose mTOR inhibitor permit phase 1A allow phase 1B . History grade 3 hypersensitivity paclitaxel . However , prior hypersensitivity patient subsequently successfully rechallenged without incident , patient may eligible investigator 's discretion . Known hypersensitivity study drug ridaforolimus component . Ridaforolimus administer caution patient know hypersensitive macrolide antibiotic , Tween80 ( polysorbate 80 ) , excipient product formulation . Significant lipid abnormality : Serum cholesterol &gt; 350mg/dL ; Triglycerides &gt; 400mg/dL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>recurrent</keyword>
	<keyword>Solid Cancer</keyword>
</DOC>